These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 3626303)

  • 1. Aluminium-related osteomalacia: response to reverse osmosis water treatment.
    Smith GD; Winney RJ; McLean A; Robson JS
    Kidney Int; 1987 Jul; 32(1):96-101. PubMed ID: 3626303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dialysate aluminium concentration and renal bone disease.
    Walker GS; Aaron JE; Peacock M; Robinson PJ; Davison AM
    Kidney Int; 1982 Feb; 21(2):411-5. PubMed ID: 7070002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological and electron microprobe studies of mineralisation in aluminium-related osteomalacia.
    Boyce BF; Byars J; McWilliams S; Mocan MZ; Elder HY; Boyle IT; Junor BJ
    J Clin Pathol; 1992 Jun; 45(6):502-8. PubMed ID: 1624597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aluminium-induced osteomalacia in severe chronic renal failure (SCRF).
    Visser WJ; Van de Vyver FL
    Clin Nephrol; 1985; 24 Suppl 1():S30-6. PubMed ID: 3915958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteomalacic dialysis osteodystrophy: Evidence for a water-borne aetiological agent, probably aluminium.
    Ward MK; Feest TG; Ellis HA; Parkinson IS; Kerr DN
    Lancet; 1978 Apr; 1(8069):841-5. PubMed ID: 76795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypercalcaemic osteomalacia due to aluminium toxicity.
    Boyce BF; Fell GS; Elder HY; Junor BJ; Elliot HL; Beastall G; Fogelman I; Boyle IT
    Lancet; 1982 Nov; 2(8306):1009-13. PubMed ID: 6127501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Water supply aluminium concentration, dialysis dementia, and effect of reverse-osmosis water treatment.
    Davison AM; Walker GS; Oli H; Lewins AM
    Lancet; 1982 Oct; 2(8302):785-7. PubMed ID: 6126664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healing of fracturing-bone disease occurring in patients on dialysis. A prospective study.
    Milne FJ; Hudson GA; Meyers AM; Baily P; Barmeir E; Dubowitz B; Reis P
    S Afr Med J; 1982 Jun; 61(25):955-9. PubMed ID: 7089762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pathogenesis of renal osteodystrophy: role of vitamin D, aluminium, parathyroid hormone, calcium and phosphorus.
    Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Johnson JR; George CR; Collett P; Kalowski S
    Q J Med; 1985 May; 55(217):127-44. PubMed ID: 4001311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of aluminum in the development of osteomalacia in patients on chronic hemodialysis].
    Adamiec R; Uzar J
    Pol Arch Med Wewn; 1988 Jan; 79(1):3-12. PubMed ID: 3275167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in bone histoquantitative parameters and histochemical staining reactions for aluminium in a group of patients with chronic renal failure following a reduction in the aluminium concentration of the haemodialysis fluid.
    McClure J; Fazzalari NL; Fassett RG; Pugsley PG
    J Clin Pathol; 1984 Jul; 37(7):743-7. PubMed ID: 6747011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aluminum-related osteomalacia: clinical and histological improvement following treatment with desferrioxamine (DFO).
    Rapoport J; Chaimovitz C; Abulfil A; Mostovlavsky M; Gazit D; Bab I
    Isr J Med Sci; 1987 Dec; 23(12):1242-6. PubMed ID: 3440748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute epidemic aluminium osteomalacia secondary to water supply contamination.
    O'Brien AA; Moore DP; Keogh JA
    Ir J Med Sci; 1990 Mar; 159(3):71-3. PubMed ID: 2361822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
    Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ
    Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteomalacia as a result of aluminum poisoning during chronic hemodialysis].
    Cournot-Witmer G; Gagnadoux MF; Lebon P; Broyer M; Balsan S
    Arch Fr Pediatr; 1982 Dec; 39 Suppl 2():749-54. PubMed ID: 6762177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone aluminum deposition in maintenance dialysis patients treated with aluminium-free dialysate: role of aluminium hydroxide consumption.
    Heaf JG; Pødenphant J; Andersen JR
    Nephron; 1986; 42(3):210-6. PubMed ID: 3945361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of aluminium in experimental osteomalacia. Preliminary results: Aluminium content and bone mineralization.
    Costantini S; Bonucci E; Mocetti P; Ballanti P; Giordano R; Vernillo I; Ioppolo A; Mantovani A; Stasolla D
    Ann Ist Super Sanita; 1986; 22(2):689-95. PubMed ID: 3752831
    [No Abstract]   [Full Text] [Related]  

  • 18. Deferoxamine-induced bone changes in haemodialysis patients: a histomorphometric study.
    Charhon SA; Chavassieux P; Boivin G; Parisien M; Chapuy MC; Traeger J; Meunier PJ
    Clin Sci (Lond); 1987 Aug; 73(2):227-34. PubMed ID: 3652627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histochemical demonstration of iron but not aluminum in a case of dialysis-associated osteomalacia.
    Phelps KR; Vigorita VJ; Bansal M; Einhorn TA
    Am J Med; 1988 Apr; 84(4):775-80. PubMed ID: 3041812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aluminium osteomalacia in chronic renal failure patients neither on dialysis nor taking aluminium containing phosphate binders.
    O'Brien AA; Moore DP; Keogh JA
    Ir J Med Sci; 1990 Mar; 159(3):74-6. PubMed ID: 2361823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.